Building on vision to create a better and
healthier every day for every woman, Organon wants to empower women
so they can be in full control of their sexual health
KIRKLAND, QC, Sept. 22, 2021 /CNW Telbec/ - Organon (NYSE:
OGN), a global women's health company, will mark this year's World
Contraception Day by launching an awareness campaign about the
global public health issue of unplanned pregnancies. As part of
this campaign, Organon Canada is partnering with the Society of
Obstetricians and Gynaecologists of Canada (SOGC) to ignite a conversation about
the surprising rates of unplanned pregnancies in Canada and the importance to educate woman on
how to choose the contraceptive method that fits their lifestyle
the most.
While it is often believed that unplanned pregnancies are no
longer an issue in Canada, nearly
50 per cent of pregnancies are unplanned, which demonstrates
that this remains an important public health issue.1 In
fact, women in the country spend at least half of their
reproductive lives at risk of an unintended
pregnancy.2 Unplanned pregnancy can impact any
woman anywhere — regardless of her social or economic background –
and poses a significant cost to individuals and society, both
directly and indirectly. It's been linked to adverse health
outcomes for both the mother and her infant.3 Worldwide,
unplanned pregnancy impacts approximately 121 million women each
year.4 A 2019 study reported that globally, more than 1
billion women have a need for family planning, but for 270 million
of them, that need for modern methods is unmet.5
"Women need to be empowered, through education, empathy and open
discussions, to make the right decisions for their body and decide
when they are ready to conceive, whether it's for the first time or
after a previous pregnancy. We aim to help foster an environment
where all women can have informed conversations with their
healthcare professional," said Amy
Cairns, Vice President of Organon Canada's Women's Health
Business.
Unintended pregnancies are not just a consequence of unprotected
sex, but other factors can lead to them, including inadequate
access or choice to the most appropriate contraceptive method. When
it comes to contraceptive methods, it is not just a one size fits
all situation. Women may benefit from learning more about the
different methods available and discuss these options with their
doctor to be able to make an informed decision.
"Canada continues to have a
high rate of unintended pregnancies. It is critical that women have
access to contraception methods that best meet their needs and
their lifestyle, including options that have been proven to be safe
and effective. Information and education can empower them to make
that choice," said Dr. Jennifer
Blake, Chief Executive Officer of the SOGC.
As a commitment to helping women in their reproductive health
journey, Organon Canada and the SOGC are bringing together women,
specialists and doctors in a virtual event on Wednesday, September 29 at 6:30 p.m. EDT to have a conversation about
unplanned pregnancy and birth control. Falling In Love with the
Right Contraception will be hosted by Dr. Jennifer Blake, the SOGC's CEO, and will feature
Dr. Ashley Waddington and Dr.
Julie Thorn.
The event will be accessible through the SOGC's Facebook page,
where people are encouraged to share their perspective to help
women take control of their full body and life, by taking control
of their birth control and ultimately reduce unplanned
pregnancy.
You can find out more about the event at
https://fb.me/e/1bgc4Gy9l
About Organon
Organon (NYSE: OGN) is a global
healthcare company formed through a spin-off from Merck, (NYSE:
MRK) known as MSD outside of the United
States and Canada, focused
on improving the health of women throughout their lives. Here for
her health, the company has a portfolio of more than 60 medicines
and products across a range of therapeutic areas. Led by the
reproductive health portfolio coupled with an expanding biosimilars
business and stable franchise of established medicines, Organon's
products produce strong cash flows that will support investments in
future growth opportunities in women's health, including business
development like recently acquired Alydia Health, a medical device
company focused on treating postpartum hemorrhage. In addition,
Organon is pursuing opportunities to collaborate with
biopharmaceutical innovators looking to commercialize their
products by leveraging its scale and presence in fast growing
international markets.
Organon has a global footprint with significant scale and
geographic reach, world-class commercial capabilities, and
approximately 9,000 employees with headquarters located in
Jersey City, New Jersey.
For more information, visit organon.com/canada-en/ and connect
with us on LinkedIn and Twitter.
Forward-Looking Statement of Organon
Except for
historical information herein, this news release includes
"forward-looking statements" within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995, including, but not limited to, statements about management's
expectations about Organon's future financial performance and
prospects. Forward-looking statements may be identified by words
such as "expects," "intends," "anticipates," "plans," "believes,"
"seeks," "estimates," "will" or words of similar meaning. These
statements are based upon the current beliefs and expectations of
the company's management and are subject to significant risks and
uncertainties. If underlying assumptions prove inaccurate or risks
or uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include, but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of the ongoing COVID-19 pandemic and emergence of
variant strains; the impact of pharmaceutical industry regulation
and health care legislation in the United
States and internationally; global trends toward health care
cost containment; technological advances; new products and patents
attained by competitors; challenges inherent in new product
development, including obtaining regulatory approval; the company's
ability to accurately predict its future financial results and
performance; the company's ability to accurately predict future
market conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the company's patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company's filings
with the Securities and Exchange Commission (SEC), including its
registration statement on Form 10, available at the SEC's Internet
site (www.sec.gov).
__________________________
|
1
|
The Society of
Obstetricians and Gynaecologists of Canada. Unintended pregnancy.
Pregnancy info Web site.
https://www.pregnancyinfo.ca/your-pregnancy/special-consideration/unintended-pregnancy/.
Accessed September 10, 2021
|
2
|
Black A, Guilbert E,
Costescu D, et al. Canadian contraception consensus (Part 1 of 4):
Chapter 1 – Contraception in Canada. J Obstet Gynaecol Can.
2015;37(10 Suppl):S5-S12.
|
3
|
Oulman E, Kim THM,
Yunis K, Tamim H. Prevalence and predictors of unintended pregnancy
among women: an analysis of the Canadian Maternity Experiences
Survey. BMC Pregnancy Childbirth.
2015;15:260-267.
|
4
|
Bearak J, Painchalk
A, Ganatra B, et al. Unintended pregnancy and abortion by income,
region, and the legal status of abortion: estimates from a
comprehensive model for 1990–2019. Lancet Glob Health.
2020;8(9):e1152-e1161.
|
5
|
Kantorová V, Wheldon
MC, Ueffing P, Dasgupta ANZ (2020) Estimating progress towards
meeting women's contraceptive needs in 185 countries: A Bayesian
hierarchical modelling study. PLoS Med. 17(2): e1003026.
*According to Kantorová et. al, modern methods of
contraception include female and male sterilization, the
intrauterine device (IUD), the implant, injectables, oral
contraceptive pills, male and female condoms, vaginal barrier
methods, the lactational amenorrhea method (LAM), emergency
contraception and other modern methods such as the contraceptive
patch or vaginal ring.
|
SOURCE Organon Canada Inc.